• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Selexipag in patients with complex or uncorrected congenital heart disease: Single centre experience.

作者信息

Meras Pablo, Merino Carlos, Gonzalez-Garcia Ana Elvira, Ruiz-Cantador Jose

机构信息

University Hospital La Paz, Department of Cardiology, Madrid, Spain.

出版信息

Int J Cardiol Congenit Heart Dis. 2022 Feb 25;8:100353. doi: 10.1016/j.ijcchd.2022.100353. eCollection 2022 Jun.

DOI:10.1016/j.ijcchd.2022.100353
PMID:39712053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11657668/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fab/11657668/dd7463fee119/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fab/11657668/ba328d889b41/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fab/11657668/dd7463fee119/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fab/11657668/ba328d889b41/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fab/11657668/dd7463fee119/gr2.jpg

相似文献

1
Selexipag in patients with complex or uncorrected congenital heart disease: Single centre experience.司来帕格用于复杂型或未经矫正的先天性心脏病患者：单中心经验
Int J Cardiol Congenit Heart Dis. 2022 Feb 25;8:100353. doi: 10.1016/j.ijcchd.2022.100353. eCollection 2022 Jun.
2
Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients.西地那非在儿科肺动脉高压中的应用：单中心报告聚焦于先天性心脏病患者。
Cardiol Young. 2021 Sep;31(9):1513-1515. doi: 10.1017/S1047951121000937. Epub 2021 Mar 30.
3
Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.司来帕格在先天性心脏病相关肺动脉高压中的当代应用：病例系列
Eur Heart J Case Rep. 2020 Nov 7;4(6):1-7. doi: 10.1093/ehjcr/ytaa320. eCollection 2020 Dec.
4
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.西地那非治疗先天性心脏病矫正后相关肺动脉高压：来自随机对照 GRIPHON 研究的见解。
Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.
5
A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients.一项针对不同类型小儿肺动脉高压患者使用司来帕格的加拿大回顾性多中心研究。
Front Pediatr. 2023 Feb 28;11:1055158. doi: 10.3389/fped.2023.1055158. eCollection 2023.
6
Real-world experience of selexipag titration in pulmonary arterial hypertension.司来帕格滴定法治疗肺动脉高压的真实世界经验
Br J Cardiol. 2021 Jul 14;28(3):32. doi: 10.5837/bjc.2021.032. eCollection 2021.
7
Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.基于司来帕格的三联联合疗法可改善中国肺动脉高压患者的预后。
Front Cardiovasc Med. 2022 Sep 20;9:991586. doi: 10.3389/fcvm.2022.991586. eCollection 2022.
8
Single-Center Experience Using Selexipag in a Pediatric Population.在儿科人群中使用司来帕格的单中心经验。
Pediatr Cardiol. 2017 Oct;38(7):1405-1409. doi: 10.1007/s00246-017-1677-7. Epub 2017 Jul 13.
9
[Experience with Selexipag to Treat Pulmonary Arterial Hypertension].[司来帕格治疗肺动脉高压的经验]
Kardiologiia. 2020 Mar 30;60(4):36-42. doi: 10.18087/cardio.2020.4.n1026.
10
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.西地那非治疗儿童肺动脉高压：药物安全性和疗效的首次多中心经验。
J Heart Lung Transplant. 2020 Jul;39(7):695-706. doi: 10.1016/j.healun.2020.03.029. Epub 2020 Apr 7.

本文引用的文献

1
Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.西地那非在艾森曼格综合征相关肺动脉高压患者中的应用。
Can J Cardiol. 2021 Aug;37(8):1286-1288. doi: 10.1016/j.cjca.2021.01.023. Epub 2021 Feb 2.
2
Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.司来帕格在先天性心脏病相关肺动脉高压中的当代应用：病例系列
Eur Heart J Case Rep. 2020 Nov 7;4(6):1-7. doi: 10.1093/ehjcr/ytaa320. eCollection 2020 Dec.
3
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
西地那非治疗先天性心脏病矫正后相关肺动脉高压：来自随机对照 GRIPHON 研究的见解。
Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.
4
Selexipag in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension and Eisenmenger Syndrome: First Report.司来帕格用于先天性心脏病相关肺动脉高压和艾森曼格综合征：首例报告
Am J Ther. 2018 Nov/Dec;25(6):e714-e715. doi: 10.1097/MJT.0000000000000727.
5
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015年欧洲心脏病学会（ESC）/欧洲呼吸学会（ERS）肺动脉高压诊断和治疗指南：欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）肺动脉高压诊断和治疗联合工作组：得到以下组织认可：欧洲儿科和先天性心脏病协会（AEPC）、国际心肺移植学会（ISHLT）。
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.
6
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.原发性肺动脉高压的生存率：依前列醇治疗的影响。
Circulation. 2002 Sep 17;106(12):1477-82. doi: 10.1161/01.cir.0000029100.82385.58.